DelveInsight’s, “Biliary Tumor Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Biliary Tumor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Biliary Tumor Research. Learn more about our innovative pipeline today! @ Biliary Tumor Pipeline Outlook

Key Takeaways from the Biliary Tumor Pipeline Report

• June 2024:- AstraZeneca- A Phase IIIb, Single Arm, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as First Line Treatment for Chinese Patients With Unresectable Biliary Tract Cancers. This is a Phase IIIb, open-label, single arm, multicentre study to assess the safety and efficacy of durvalumab in combination with investigator’s choice of 3 different gemcitabine-based chemotherapy regimens in participants with aBTC with a WHO/ECOG PS of 0 to 2 at enrolment.
• June 2024:- UNICANCER- Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial. The object of this trial is to evaluate whether the introduction of a targeted therapy after 4 cycles of the current standard-of-care treatment for advanced biliary cancer is superior to continuing with the standard treatment.
• DelveInsight’s Biliary Tumor pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Biliary Tumor treatment.
• The leading Biliary Tumor Companies such as Jazz Pharmaceuticals, TransThera Sciences, Chia Tai Tianqing Pharmaceutical, Jiangsu HengRui Medicine, RemeGen, Shanghai Miracogen, ModeX Therapeutics, Intensity Therapeutics, GeneQuantum Healthcare, Elicio Therapeutics, SystImmune, Lanova Medicines Limited, and others.
• Promising Biliary Tumor Therapies such as Durvalumab, Futibatinib, Ivosidenib, Zanidatamab, Gemcitabine & Cisplatin, KN035, XmAb20717, ZW25 (Zanidatamab), and others.

Stay informed about the cutting-edge advancements in Biliary Tumor Treatments. Download for updates and be a part of the revolution in cancer care @ Biliary Tumor Clinical Trials Assessment

Biliary Tumor Emerging Drugs Profile

• Rilvegostomig: AstraZeneca

Rilvegostomig (formerly AZD2936) is a bispecific antibody developed by AstraZeneca, targeting both PD-1 and TIGIT to enhance immune responses against cancer. Derived from Compugen’s COM902 antibody, it aims to maximize the blockade of these pathways through cooperative binding, potentially improving therapeutic outcomes. Scheduled to progress into Phase III trials for indications like Biliary cancer, non-small cell lung cancer and gastric cancer, rilvegostomig is also being evaluated in combination with AstraZeneca’s antibody-drug conjugates such as Enhertu, Dato-DXd, and AZD0901, as part of a strategy to leverage its differentiated bispecific format for greater efficacy.

• SHR-A1811: Jiangsu HengRui Medicine

SHR-A1811 is an antibody-drug conjugate (ADC) composed of trastuzumab, a cleavable linker, and a novel topoisomerase I inhibitor payload called SHR169265. It targets HER2-expressing tumor cells, delivering the cytotoxic payload upon internalization. Once inside the cell, the linker is cleaved, releasing SHR169265 which inhibits topoisomerase I, an essential enzyme for DNA replication and transcription, leading to cell cycle arrest and apoptosis. SHR-A1811 has shown promising antitumor activity in preclinical models and is currently being evaluated in multiple phase I-III clinical trials for HER2-positive and HER2-low breast cancer, gastric cancer, and other solid tumors. Currently, the drug is in Phase II stage of its clinical trial for the treatment of biliary cancer.

• AMG 193: Amgen

AMG 193 is a small molecule methylthioadenosine (MTA) cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor. It is being investigated for the treatment of solid tumors. Currently, the drug is in Phase I stage of its clinical trial for the treatment of biliary cancer.

Learn more about Biliary Tumor Drugs opportunities in our groundbreaking Biliary Tumor Research and development projects @ Biliary Tumor Unmet Needs

Biliary Tumor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Biliary Tumor Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Biliary Tumor Market Drivers and Barriers, and Future Perspectives

Scope of the Biliary Tumor Pipeline Report

• Coverage- Global
• Biliary Tumor Companies- Jazz Pharmaceuticals, TransThera Sciences, Chia Tai Tianqing Pharmaceutical, Jiangsu HengRui Medicine, RemeGen, Shanghai Miracogen, ModeX Therapeutics, Intensity Therapeutics, GeneQuantum Healthcare, Elicio Therapeutics, SystImmune, Lanova Medicines Limited, and others.
• Biliary Tumor Therapies- Durvalumab, Futibatinib, Ivosidenib, Zanidatamab, Gemcitabine & Cisplatin, KN035, XmAb20717, ZW25 (Zanidatamab), and others.
• Biliary Tumor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Biliary Tumor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Biliary Tumor Biliary Tumor Pipeline on our website @ Biliary Tumor Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Biliary Tumor: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Biliary Tumor– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Rilvegostomig: AstraZeneca
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. SHR-A1811: Jiangsu HengRui Medicine
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. AMG 193: Amgen
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Biliary Tumor Key Companies
21. Biliary Tumor Key Products
22. Biliary Tumor- Unmet Needs
23. Biliary Tumor- Market Drivers and Barriers
24. Biliary Tumor- Future Perspectives and Conclusion
25. Biliary Tumor Analyst Views
26. Biliary Tumor Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/